US regulators on Monday put an experimental immunotherapy agent on the fast track to market approval, after 89 percent of leukemia patients in early trials saw their cancers disappear. The personalized immunotherapy known as CTL019 was developed by the University of Pennsylvania and was designated a "breakthrough therapy" by the US Food and Drug Administration. It is the first cancer immunotherapy to receive the breakthrough designation, and only the fifth biologic agent so far. The approach works by extracting a patient's T-cells, then genetically programming them in the lab to target cancer cells that produce a protein called CD19.
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment